Back to School: How biopharma can reboot drug development. Access exclusive analysis here

InterMune raises $68.3 million

ITMN raised $68.3 million through the sale

Read the full 74 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE